Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
35.91
+2.64 (7.94%)
Dec 20, 2024, 4:00 PM EST - Market closed
Tandem Diabetes Care Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for TNDM stock have an average target of 52.06, with a low estimate of 24 and a high estimate of 75. The average target predicts an increase of 44.97% from the current stock price of 35.91.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for TNDM stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Buy | 6 | 5 | 5 | 6 | 7 | 8 |
| Hold | 2 | 3 | 3 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 15 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $57 → $50 | Strong Buy | Maintains | $57 → $50 | +39.24% | Dec 11, 2024 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $45 | Hold → Buy | Upgrades | $45 | +25.31% | Dec 2, 2024 |
| Barclays | Barclays | Buy Maintains $58 → $60 | Buy | Maintains | $58 → $60 | +67.08% | Nov 8, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $57 → $56 | Strong Buy | Maintains | $57 → $56 | +55.95% | Nov 7, 2024 |
| Baird | Baird | Hold Maintains $39 → $37 | Hold | Maintains | $39 → $37 | +3.04% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
927.01M
from 747.72M
Increased by 23.98%
Revenue Next Year
1.03B
from 927.01M
Increased by 10.89%
EPS This Year
-1.74
from -3.43
EPS Next Year
-1.22
from -1.74
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 985.5M | 1.1B | 1.3B | |||
| Avg | 927.0M | 1.0B | 1.1B | |||
| Low | 885.2M | 885.2M | 1.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 31.8% | 19.5% | 24.9% | |||
| Avg | 24.0% | 10.9% | 11.8% | |||
| Low | 18.4% | -4.5% | 3.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.60 | -0.76 | -0.28 | |||
| Avg | -1.74 | -1.22 | -0.73 | |||
| Low | -1.82 | -1.48 | -1.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.